CD38 and neoplasm: Importantly, CD38‐EVs exhibited substantially reduced uptake by non‐tumour stromal cells than standard EVs, demonstrating their potential safety for delivering chemotherapeutic agents by targeting tumour cells and sparing non‐tumour cells.